Bristol-Myers Squibb focuses on analyst expectations, shares in S&P 500 spotlight

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 10:06.

Bristol-Myers Squibb (US1078421011) trades on the NYSE under the ticker BMY and is part of the S&P 500 health care cohort. Zacks reports that the pharmaceutical group delivered a clear earnings surprise in the first quarter of 2026, which shapes current analyst expectations for the stock. Zacks coverage of the Q1 figures

What the latest earnings show

For the quarter ended March 2026, Bristol-Myers Squibb reported adjusted earnings of 1.58 US dollars per share, compared with a Zacks Consensus Estimate of 1.44 dollars per share. This represents an earnings surprise of 9.67 percent, according to the Zacks report. Zacks recap of the quarter

Revenue in the same period reached 11.49 billion US dollars, exceeding the Zacks Consensus Estimate by 5.25 percent. The earnings per share were lower than the 1.80 dollars reported a year earlier, but the top line illustrates a solid sales base in a competitive pharmaceutical environment. Detailed Zacks figures

How analysts view the Bristol-Myers Squibb shares

Analyst platforms such as MarketBeat list Bristol-Myers Squibb as a major NYSE-listed pharmaceutical player with a closing share price of 55.33 US dollars on 25 June 2026 and post-market trading at 55.65 dollars. The stock trades in the MED - BIOMED/GENE industry cluster, which includes peers such as Merck & Co. and Pfizer. MarketBeat profile for BMY

Consensus data on platforms like Zacks and MarketBeat indicate that analysts monitor the earnings trajectory and the company’s ability to manage patent expiries and oncology competition. Rating distributions and price targets cluster around mid-double-digit dollar levels, which underlines a cautious but engaged analyst stance on the Bristol-Myers Squibb shares. Zacks overview page for BMY

How the company earns its money

Bristol-Myers Squibb generates most of its revenue from patented prescription medicines in oncology, immunology, cardiovascular and hematology. Flagship products include the cancer immunotherapy Opdivo and the anticoagulant Eliquis, which together contribute a substantial portion of annual group sales.

Where the BMY shares trade today

The Bristol-Myers Squibb shares (US1078421011) last closed on 2026-06-25 at 55.33 US dollars on the NYSE, according to MarketBeat, with after-hours indications at 55.65 dollars for the same date and venue.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data are based on sources considered reliable but cannot be guaranteed.